The Company’s leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription drug products and a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals:
For patients, MonoSol Rx’s aim is to develop drugs that are easier to take, non-invasive and use less drug for the same effect. Specifically, PharmFilm® offers the greatest impact in patient populations where compliance may be a challenge – pediatric, geriatric and psychiatric – or where convenience and onset-of-action are essential – asthma, diabetes, migraine and ADHD.
For pharmaceutical partners, MonoSol Rx’s value proposition is two-fold. PharmFilm® creates differentiated products that are ideal for extending the revenue lifecycle for drugs with patent lives that have expired or are approaching expiration. Additionally, for innovators that are looking to introduce new drugs to the market, PharmFilm® provides a platform for developing unique products that are highly marketable because they offer easily-recognized benefits to patients and caregivers.
The purpose of MonoSol Rx is to apply our PharmFilm® technology, alone or in combination with others, in order to improve healthcare for patients by enhancing: